# Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

> **NCT00381654** · PHASE1 · TERMINATED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** AV-412

## Key facts

- **NCT ID:** NCT00381654
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2009-12
- **Final completion:** 2010-02
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Study did not meet pre-specified objectives.
- **Last updated:** 2011-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381654, "Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00381654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*